(Press-News.org) Boston – Four teams of Dana-Farber Cancer Institute investigators have found that people experience discrimination and bias in different ways and in more realms of cancer care than previously understood. The findings, in different studies, suggest that oncology professionals and the systems they work in have more work to do to adapt to the realities of increasing diversity and inclusion, not only in the patient population but also in the oncology workforce. The research teams will present their findings at the 2024 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago. ASCO is the world’s largest clinical cancer research meeting, attracting more than 30,000 global oncology professionals.
“We need to transform our health systems so that they work for everybody,” says presenter Shail Maingi, MD, a member of Dana-Farber’s Cancer Care Equity Program and a physician at the Dana-Farber Brigham Cancer Center at South Shore Health. “These findings bring to light disparities and interpersonal dynamics that are surprising and important for us to pay attention to as we strive to build medical systems that see and take care of everyone.”
LGBTQ+: Patient and physician experiences
Maingi is presenting two abstracts and reporting data from a survey of 817 LGBTQ+ cancer patients and 115 oncology professionals from a wide range of treatment centers in the U.S. The survey revealed that while 84% of physicians reported feeling comfortable treating LGBTQ+ patients, only 24% of patients felt comfortable disclosing their LGBTQ+ status. In addition, a scant 4% of patients felt that their care team treated their partner with respect. At least 30% of physicians reported being unsure how LGBTQ+ status affected treatment considerations or how to discuss LGBTQ+ status with their patients.
Maingi’s team used the survey responses to develop a toolkit to improve LGBTQ+ patient experiences. Her team shared that toolkit with several community sites and discussed initiatives the sites could implement rapidly, within 30 days.
Many of these initiatives are already in place at Dana-Farber. “Dana-Farber is becoming more approachable and diverse, so we are starting to understand the lived experiences of our patients. This knowledge is making the Institute stronger,” says Maingi. “But we don’t have this solved.”
Study Title: Disparities uncovered: LGBTQ+ patients report on their cancer care journey Abstract Number: 1516 Session: Rapid Oral Abstract Session - Care Delivery/Models of Care; June 3, 2024, 7:00am ET Presenting Author: Shail Maingi, MD
Study Title: Beyond the binary: A transformative implementation science initiative to improve LGBTQ+ cancer care Abstract Number: 11010 Session: Rapid Oral Abstract Session - Quality Care/Health Services Research; June 3, 2024, 12:21pm ET Presenting Author: Shail Maingi, MD
International medical graduates face unconscious bias and limited opportunities
Three other abstracts will be presented during the conference that focus on oncology professionals who are international medical graduates, meaning they attended medical school outside of the U.S. or Canada but completed residency and fellowships and are now practicing in the U.S. Approximately 30% of U.S. oncology professionals are international medical graduates.
International medical graduates, like author Narjust Florez, MD, Associate Director of the Cancer Care Equity Program and a thoracic medical oncologist at Dana-Farber, help diversify the oncology workforce so that it more closely mirrors the populations of patients it serves. Florez, however, will report that being an international medical graduate in the U.S. is difficult.
Her team’s survey of 97 oncologists who are international, or Puerto Rican medical graduates revealed that over half experienced racial or ethnic discrimination during training and independent practice. In addition, women were more likely to face racial or ethnic discrimination during training than men and were more likely to experience gender discrimination during training and clinical practice, demonstrating the power of intersectionality between different types of biases, including gender bias.
“Unconscious bias is an extra thing that international medical graduates need to deal with,” says Florez, who has personal experience with bias. “My race and my accent come through the door before any of my credentials, titles, and publications.”
International medical graduates may also have fewer opportunities to be invited as faculty. Findings by senior author Toni Choueiri, MD, Director of the Lank Center for Genitourinary Oncology at Dana-Farber, will be presented from an analysis of event programs from the two previous ASCO annual meetings. This team found that international medical graduates who are practicing oncologists in the US are less likely to be invited as faculty presenters at ASCO than their American medical graduate counterparts, even when they produce the same amount of original research.
Study Title: Going back home: Understanding the challenges of international medical graduates (IMGs) in oncology Abstract Number: 9001 Session: Clinical Science Symposium - Conflicts (of Interest) and Conundrums: Perspectives From the Global Oncology Community; June 1, 2024, 12:39pm ET Senior Author: Narjust Florez, MD
Study Title: Assessing gender disparities in oncology: Less talk, more action Abstract Number: 9011 Session: Rapid Oral Abstract Session - Medical Education and Professional Development; June 3, 2024, 9:57am ET Senior Author: Narjust Florez, MD
Study Title: International medical graduates (IMG) representation at international oncology conference meetings Abstract Number: 9000 Session: Clinical Science Symposium - Conflicts (of Interest) and Conundrums: Perspectives From the Global Oncology Community; June 1, 2024, 12:27pm ET Senior Author: Toni Choueiri, MD
Experiences of discrimination and financial stress, not race, associated with mistrust in health care systems
Social determinants of health (the conditions a person is born, lives, and ages in) and not race were associated with a lack of engagement with and trust of health care systems, according to findings reported by Dana-Farber’s Breast Oncology Program. Rachel Freedman, MD, MPH, a clinician-scientist in Dana-Farber’s Breast Oncology Program is the senior author of the study, which is presented and led by Olga Kantor, MD, MS, of Dana-Farber Brigham Cancer Center.
The team surveyed 297 women (a mix of 60% white, 25% Black, and 15% Hispanic people). Analysis associates experiences of discrimination in daily life and in health care, such as being treated with less courtesy or as if dishonest, with avoiding information about cancer, not initiating recommended treatment for cancer, and mistrust of physicians. Financial strain, such as concerns about medical bills or not having insurance, was also associated with these end results. Race and ethnicity were not associated with any of these outcomes.
Study Title: Associations of social determinants of health with avoidance of information, treatment receipt, and physician mistrust for women with breast cancer Abstract Number: 1507 Session: Oral Abstract Session - Care Delivery/Models of Care; June 4, 2024, 10:57am ET Presenting Author: Olga Kantor, MD Senior Author: Rachel Freedman, MD, MPH
These findings are among more than 80 studies presented at ASCO that are led by Dana-Farber-affiliated researchers.
A full list of Dana-Farber Oral Presentations at the 2024 ASCO Annual Meeting is available here.
A full list of Dana-Farber Poster Discussions at the 2024 ASCO Annual Meeting is available here.
For all ASCO-related media inquiries, call, or email Victoria Warren, 617-939-5531, Victoria_Warren@dfci.harvard.edu. Follow the meeting live on X using the hashtag #ASCO24 and follow Dana-Farber News on X at @DanaFarberNews.
About Dana-Farber Cancer Institute
Dana-Farber Cancer Institute is one of the world’s leading centers of cancer research and treatment. Dana-Farber’s mission is to reduce the burden of cancer through scientific inquiry, clinical care, education, community engagement, and advocacy. We provide the latest treatments in cancer for adults through Dana-Farber Brigham Cancer Center and for children through Dana-Farber/Boston Children’s Cancer and Blood Disorders Center. Dana-Farber is the only hospital nationwide with a top 10 U.S. News & World Report Best Cancer Hospital ranking in both adult and pediatric care.
As a global leader in oncology, Dana-Farber is dedicated to a unique and equal balance between cancer research and care, translating the results of discovery into new treatments for patients locally and around the world, offering more than 1,100 clinical trials.
###
END
Dana-Farber researchers uncover disparities in lived experiences for patients and physicians
2024-05-30
[Attachments] See images for this press release:
ELSE PRESS RELEASES FROM THIS DATE:
Mayo scientists developing at-home swab tests for endometrial, ovarian cancer
2024-05-30
ROCHESTER, Minnesota — Early detection improves treatment outcomes for endometrial and ovarian cancers, yet far too often women are diagnosed in advanced stages of these diseases. Unlike many other cancers, there are no standard screenings for early detection of endometrial and ovarian cancers. The incidence rate for endometrial cancer is expected to rise, driven by environmental factors, obesity and diabetes.
Marina Walther-Antonio, Ph.D., and colleagues at Mayo Clinic's Center for Individualized Medicine are on a mission to catch these cancers early.
Their research dives deep into the microbiome, a community of ...
UAB researchers uncover protein SRSF1’s uncommon ability to bind and unfold RNA G-quadruplexes
2024-05-30
BIRMINGHAM, Ala. – RNA transcription is the genomic process in which a cell produces a duplicate of a gene’s DNA sequence.
In a study published in Nucleic Acids Research, University of Alabama at Birmingham Department of Chemistry Professor Jun Zhang, Ph.D., and his team reveal how the protein SRSF1 possesses the novel function of binding and unfolding complex RNA Guanine-quadruplexes.
Present in both DNA and RNA sequences, a G-quadruplex (GQ) is a structure of four guanine bases attached in a planar array. ...
New study reveals key protein that could help prevent excessive bone loss in osteoporosis
2024-05-30
Osteoporosis, a condition characterized by porous and fragile bones, poses a significant threat to skeletal health. As the very framework of the human body, bones provide crucial structural support. When bone mass diminishes, it not only compromises this support but also impairs overall function, leading to a diminished quality of life. With the aging population experiencing a surge in osteoporosis cases, the strain on healthcare resources for long-term care is evident. Hence, there is a need to understand the mechanisms that contribute to osteoporosis and develop effective targeted therapies ...
Testosterone therapy: A safe and effective gender-affirming hormone therapy for trans men
2024-05-30
Transgender individuals often face unique challenges in aligning their physical bodies with their true gender identity. Among the various methods employed, gender-affirming hormone therapy (GAHT) stands as a vital means for transgender men to achieve physical changes in consonance with their gender identity. Navigating the complexities that come with gender transition, transgender individuals seek medical interventions to alleviate gender dysphoria and align their bodies with their gender identity.
For transgender men, testosterone therapy holds promise in inducing masculinizing effects such as increased muscle mass, cessation of ...
Statisticians call for rigour and transparency in the evaluation of diagnostic tests
2024-05-30
Recommendations designed to reframe the evaluation of in vitro diagnostic tests have been published today by the Royal Statistical Society in its Series A journal.
The report, which will be submitted to the UK Covid-19 Inquiry, is intended to help prevent future scenarios in which IVDs are marketed widely, but later attract serious concerns about the standards applied to their evaluation.
The research was prompted by concerns about the standards applied to the evaluation of diagnostic tests during the Covid-19 pandemic – particularly lateral flow tests – however the recommendations cover all new tests, especially those ...
Musankwa sanyatiensis, a new dinosaur from Zimbabwe
2024-05-30
Fossils found on the shoreline of Lake Kariba in Zimbabwe represent a completely new dinosaur species. This remarkable find, named Musankwa sanyatiensis, marks only the fourth dinosaur species named from Zimbabwe. The research detailing this significant discovery is set to be published in the prestigious journal Acta Palaeontologica Polonica. The study was conducted by an international team of scientists from the University of the Witwatersrand (Wits) in South Africa, the Natural History Museum of Zimbabwe, Stony Brook University in New York and was led by Prof Paul Barrett from the Natural History Museum ...
Statin therapy may prevent cancer by blocking inflammatory protein
2024-05-30
BOSTON – A new study led by investigators from Mass General Cancer Center, a founding member of the Mass General Brigham healthcare system, reveals that statins—commonly used cholesterol-lowering drugs—may block a particular pathway involved in the development of cancer that results from chronic inflammation. The findings are published in Nature Communications.
“Chronic inflammation is a major cause of cancer worldwide,” said senior author Shawn Demehri, MD, PhD, a principal investigator at the Center for Cancer Immunology and Cutaneous Biology Research Center of Massachusetts General Hospital and an associate professor of Dermatology at ...
A novel ‘senolytic’ strategy for treating aging-related diseases
2024-05-30
The process of aging is accompanied by a decline in physiological functions, which can lead to cardiovascular, neurodegenerative, and metabolic diseases. Aging of cells, also known as ‘cellular senescence’— is a process in which a cell ages and permanently stops dividing but does not die. The accumulation of such ‘senescent’ cells in tissues is then known to contribute to age-associated diseases. Elimination of senescent cells or ‘senolysis’ can, therefore, serve as an effective therapeutic strategy for the improvement of physiological function and prevention ...
Risk of death from COVID-19 lessens, but infection still can cause issues 3 years later
2024-05-30
New findings on long COVID — long-term effects on health experienced by many who have had COVID-19 — present a good-news, bad-news situation, according to a study at Washington University School of Medicine in St. Louis and the Veterans Affairs St. Louis Health Care system.
The bad news: COVID-19 patients who were hospitalized within the first 30 days after infection face a 29% higher risk of death in the third year compared with people who have not had the virus. However, the three-year death risk still marks a significant decline compared with such risk at the one- and two-year marks post-infection. The findings also show that even people with mild COVID-19 were still ...
Combining simulations and experiments to get the best out of Fe3Al
2024-05-30
Osaka, Japan – The compound of iron and aluminum with the chemical formula Fe3Al has some very useful mechanical properties. A team from Osaka University has combined simulations with experimental techniques to better understand the kinetics of the formation of microstructures to enhance and utilize these properties and how to harness them for specific applications.
In a study recently published in Acta Materialia, the researchers took an in-depth look at the way the microstructure of Fe3Al develops because the ordered domains that form contribute to one of its key properties: superelasticity.
When high loads are applied to superelastic materials they ...